Caveolin-1 is involved in radiation-induced ERBB2 nuclear transport in breast cancer cells

Abstract

This study examined the radiation-induced ERBB2 nuclear transport in the BT474 breast cancer cell line and the relationship between caveolin-1 and radiation-induced ERBB2 nuclear transport. The BT474 cells were treated with herceptin (200 nmol/L), PP2 (a caveolin-1 inhibitor, 100 nmol/L) and irradiation combined or alone. Confocal microscopy was used to observe the nuclear import of ERBB2 and caveolin-1 after irradiation. Western blotting was employed to detect the expression of ERBB2, caveolin-1 and DNA-PKcs after irradiation, and immunoprecipitation to identify the ERBB2 and caveolin-1 complex before perinuclear ERBB2 localization. Confocal microscopy showed the transport of ERBB2 and caveolin-1 from the cell membrane to the nucleus 15 min after irradiation and the proteins accumulated at the perinuclear region within 45 min. Western blotting revealed that the expression levels of ERBB2, caveolin-1 and DNA-PKcs were increased after irradiation and reached a peak 45 min later. Both herceptin and PP2 treatments were found to decrease ERBB2 expression. An immune complex composed of ERBB2 and caveolin-1 was found in the herceptin group after irradiation. It was concluded that after irradiation, ERBB2 may be transported from the cell membrane to the nucleus and activate DNA-PKcs to trigger DNA double-strand break (DSB) repair; caveolin-1 may participate in this process. Treatments involving the downregulation of caveolin-1 may increase the radiosensitization of breast cancer cells.

Keywords

ERBB2 / caveolin-1 / radiation / nuclear transport

References

[1] LeeC.M., ShrieveD.C., ZempolichK.A., et al.. Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol Oncol, 2005, 99(2): 415-421

[2] AkamatsuM., MatsumotoT., OkaK., et al.. c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys, 2003, 57(5): 1323-1327

[3] LiangK., LuY., JinW., et al.. Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther, 2003, 2(11): 1113-1120

[4] PietrasR.J., PoenJ.C., GallardoD., et al.. Monoclonal antibody to HER-2/neu receptor modulates repair of radiationinduced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res, 1999, 59(6): 1347-1355

[5] GuoG., WangT., GaoQ., et al.. Expression of ErbB2 enhances radiation-induced NF-κB activation. Oncogene, 2004, 23(2): 535-545

[6] LuoB., YuS., ZhuangL., et al.. Induction of ERBB2 nuclear transport after radiation in breast cancer cells. J Huazhong Univ Sci Technol [Med Sci], 2009, 29(3): 350-353

[7] DittmannK., MayerC., KehlbachR., et al.. Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport, activation of DNA-PK. Mol Cancer, 2008, 7: 69

[8] DiermeierS., HorváthG., Knuechel-ClarkeR., et al.. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res, 2005, 304(2): 604-619

[9] ToulanyM., MinjgeeM., KehlbachR., et al.. ErbB2 expression through heterodimerization with erbB1 is necessary for ionizing radiation-but not EGF-induced activation of Akt survival pathway. Radiother Oncol, 2010, 97(2): 338-345

[10] FukutomeM., MaebayashiK., NasuS., et al.. Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 (“Iressa”) and trastuzumab (“Herceptin”). Int J Radiat Oncol Biol Phys, 2006, 66(2): 528-536

[11] HortonJ.K., HalleJ., FerraroM., et al.. Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase trial. II Int J Radiat Oncol Biol Phys, 2010, 76(4): 998-1004

[12] AliS.M., CarneyW.P., EstevaF.J., et al.. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer, 2008, 113(6): 1294-1301

[13] MolinaM.A., Codony-ServatJ., AlbanellJ., et al.. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res, 2001, 61(12): 4744-4749

[14] ValabregaG., MontemurroF., SarottoI., et al.. TGFalpha expression impairs Trastuzumab-induced HER2 downregulation. Oncogene, 2005, 24(18): 3002-3010

[15] NahtaR., YuanL.X., ZhangB., et al.. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res, 2005, 65(23): 11118-11128

[16] AustinC.D., De MazièreA.M., PisacaneP.I., et al.. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell, 2004, 15(12): 5268-5282

[17] GiriD.K., Ali-SeyedM., LiL.Y., et al.. Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor. Mol Cell Biol, 2005, 25(24): 11005-11018

[18] KhanE.M., HeidingerJ.M., LevyM., et al.. Epidermal growth factor receptor exposed to oxidative stress undergoes Src- and caveolin-1-dependent perinuclear trafficking. J Biol Chem, 2006, 281(20): 14486-14493

[19] DittmannK., MayerC., KehlbachR., et al.. Radiation-induced lipid peroxidation activates src kinase and triggers nuclear EGFR transport. Radiother Oncol, 2009, 92(3): 379-382

[20] ZhuH., YueJ., PanZ., et al.. Involvement of Caveolin-1 in repair of DNA damage through both homologous recombination and non-homologous end joining. PLoS One, 2010, 5(8): e12055

[21] LiC., IidaM., DunnE.F., et al.. Dasatinib blocks cetuximab-and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma. Radiother Oncol, 2010, 97(2): 330-337